Alanyl-Glutamine Dipeptide Attenuates Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice by Improving Gut Microbiota Dysbiosis
Nutrients · 14.09.2023 · 15 (18) · 3988
DOI: 10.3390/nu15183988 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 14.09.2023. Verfasst von Yigang Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Drug Discovery Technology, Ningbo University, Ningbo 315211, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Gastrointestinal Microbiome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation, Natural Science Foundation of Ningbo City, Scientific Research Grant of Ningbo University.
Abstract (Originalsprache)
Non-alcoholic fatty liver disease (NAFLD) manifests as a persistent liver ailment marked by the excessive buildup of lipids within the hepatic organ accompanied by inflammatory responses and oxidative stress. Alanyl-glutamine (AG), a dipeptide comprising alanine and glutamine, is commonly employed as a nutritional supplement in clinical settings. This research aims to evaluate the impact of AG on NAFLD triggered by a high-fat diet (HFD), while concurrently delving into the potential mechanisms underlying its effects. The results presented herein demonstrate a notable reduction in the elevated body weight, liver mass, and liver index induced by a HFD upon AG administration. These alterations coincide with the amelioration of liver injury and the attenuation of hepatic histological advancement. Furthermore, AG treatment manifests a discernible diminution in oil-red-O-stained regions and triglyceride (TG) levels within the liver. Noteworthy alterations encompass lowered plasma total cholesterol (TC) and low-density lipoprotein cholesterol (LDLC) concentrations, coupled with elevated high-density lipoprotein cholesterol (HDLC) concentrations. The mitigation of hepatic lipid accumulation resultant from AG administration is aligned with the downregulation of ACC1, SCD1, PPAR-γ, and CD36 expression, in conjunction with the upregulation of FXR and SHP expression. Concomitantly, AG administration leads to a reduction in the accumulation of F4/80-positive macrophages within the liver, likely attributable to the downregulated expression of MCP-1. Furthermore, AG treatment yields a decline in hepatic MDA levels and a concurrent increase in the activities of SOD and GPX. A pivotal observation underscores the effect of AG in rectifying the imbalance of gut microbiota in HFD-fed mice. Consequently, this study sheds light on the protective attributes of AG against HFD-induced NAFLD through the modulation of gut microbiota composition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Drug Discovery Technology, Ningbo University, Ningbo 315211, China.
- Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Ningbo University, Ningbo 315211, China.
Förderung
- Zhejiang Provincial Natural Science Foundation
- Natural Science Foundation of Ningbo City
- Scientific Research Grant of Ningbo University
- Ningbo Top Talent Project
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Zheng, Y., Ying, H., Shi, J., Li, L., & Zhao, Y. (2023). Alanyl-Glutamine Dipeptide Attenuates Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice by Improving Gut Microbiota Dysbiosis. Nutrients, 15(18), 3988. https://doi.org/10.3390/nu15183988
Vancouver
Zheng Y, Ying H, Shi J, Li L, Zhao Y. Alanyl-Glutamine Dipeptide Attenuates Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice by Improving Gut Microbiota Dysbiosis. Nutrients. 2023;15(18):3988. doi:10.3390/nu15183988
BibTeX
@article{Zheng2023,
author = {Zheng, Yigang and Ying, Hanglu and Shi, Jiayi and Li, Long and Zhao, Yufen},
title = {Alanyl-Glutamine Dipeptide Attenuates Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice by Improving Gut Microbiota Dysbiosis},
journal = {Nutrients},
year = {2023},
volume = {15},
number = {18},
pages = {3988},
doi = {10.3390/nu15183988}
}
EUVIMED